Prosecution Insights
Last updated: October 04, 2026

BEIJING ZHENDONG GUANGMING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD.

Technology area: Chemistry & Materials

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

BEIJING ZHENDONG GUANGMING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. has 1 pending office action in Chemistry & Materials. This involves a distinct examiner and a single art unit. The focus on chemistry suggests that the company's current intellectual property efforts are directed toward pharmaceutical or material science developments.

XU, XIAOYUN is the busiest examiner for this portfolio. This examiner is managing 1 busiest examiner pending office action, which is the only pending action currently active for the company. Having the entire workload under a single examiner allows for a centralized prosecution process, where the applicant can focus on the specific requirements of one individual.

Practitioners should consider that the prosecution outcome is heavily dependent on the examiner's perspective on the chemical arts. The alignment of the technology area with the assigned art unit indicates that the application is being reviewed by specialists in chemistry. Effective prosecution will require a detailed technical response that addresses the specific prior art and legal standards applied within this art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
XU, XIAOYUN 1 60.0% +31.8%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18255302 METHOD FOR DETECTING MONOSACCHARIDE AND OLIGOSACCHARIDE CONTENT AND FINGERPRINT SPECTURM OF COMPOUND SOPHORA FLAVESCENS INJECTION XU, XIAOYUN —

Top Art Units

Art UnitApps
1797 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18255302 METHOD FOR DETECTING MONOSACCHARIDE AND OLIGOSACCHARIDE CONTENT AND FINGERPRINT SPECTURM OF COMPOUND SOPHORA FLAVESCENS INJECTION XU, XIAOYUN 1797 §103 Non-Final OA — Pending May 31, 2023

Managing BEIJING ZHENDONG GUANGMING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month